Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$10.74 USD
+0.46 (4.47%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $10.75 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.74 USD
+0.46 (4.47%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $10.75 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Zacks News
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
by Zacks Equity Research
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Cogent Biosciences, Inc. (COGT) points to a 78.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength
by Zacks Equity Research
Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
by Zacks Equity Research
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
by Zacks Equity Research
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
Company News for Jun 13, 2022
by Zacks Equity Research
Companies In The News Are: DOCU, COGT, BA, SFIX.
Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for November 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for November 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Can the Rally in Cogint (COGT) Shares Continue?
by Zacks Equity Research
Cogint, Inc. (COGT) has been on the move lately as the stock has risen by 17.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
Should You Buy Cogint (COGT) Ahead of Earnings?
by Zacks Equity Research
Cogint (COGT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Cogint, Inc. (COGT) Jumps: Stock Rises 6.9%
by Zacks Equity Research
Cogint, Inc. (COGT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.
Falling Earnings Estimates Signal Weakness Ahead for Cogint (COGT)
by Zacks Equity Research
It seems to be a wise decision for investors to drop Cogint (COGT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Can IDI (COGT) Run Higher on Strong Earnings Estimate Revisions?
by Anupama Mukhopadhyay
On the back of solid estimate revisions, investors may definitely want to consider this Zacks Rank #2 IDI (COGT) stock to profit in the near future.
Cogint (COGT): An Off-the-Radar Potential Winner
by Zacks Equity Research
Cogint (COGT) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Acxiom Teams Up with Verve to Boost Mobile-based Marketing
by Zacks Equity Research
Acxiom (ACXM), a formidable player in the field of marketing services and technology, has announced a partnership with Verve, for location-powered mobile marketing.